Savara Inc (NASDAQ:SVRA – Get Free Report) has earned a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $11.00.
Several equities research analysts recently weighed in on SVRA shares. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price target on shares of Savara in a report on Monday, May 6th. HC Wainwright raised their target price on Savara from $6.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Oppenheimer lifted their price target on Savara from $11.00 to $15.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 26th. Guggenheim lifted their price target on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, June 27th. Finally, Evercore ISI cut their price target on Savara from $10.00 to $7.00 and set an “outperform” rating for the company in a research note on Thursday, May 16th.
Check Out Our Latest Research Report on Savara
Hedge Funds Weigh In On Savara
Savara Stock Performance
Shares of SVRA opened at $4.96 on Wednesday. The company has a current ratio of 14.90, a quick ratio of 14.90 and a debt-to-equity ratio of 0.22. The firm has a market cap of $685.42 million, a PE ratio of -13.41 and a beta of 1.00. The company’s 50 day simple moving average is $4.30 and its 200-day simple moving average is $4.63. Savara has a 12-month low of $3.07 and a 12-month high of $5.70.
Savara (NASDAQ:SVRA – Get Free Report) last announced its earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). As a group, equities analysts predict that Savara will post -0.41 EPS for the current year.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading
- Five stocks we like better than Savara
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Tech Leader’s Stock Split: Is It the Right Time to Buy?
- Canadian Penny Stocks: Can They Make You Rich?
- Could the Economy be Bottoming? Major Bank’s Earnings Say Yes
- What is a buyback in stocks? A comprehensive guide for investors
- Seize This Prime Stock Opportunity on Amazon Prime Days
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.